FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F22%3AA2402KED" target="_blank" >RIV/61988987:17110/22:A2402KED - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/22:00128261 RIV/61989592:15110/22:73614704 RIV/00098892:_____/22:10157168 RIV/00843989:_____/22:E0109681 RIV/00209805:_____/22:00079051

Výsledek na webu

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000845752300001" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000845752300001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/jpm12081245" target="_blank" >10.3390/jpm12081245</a>

Jazyk výsledku

angličtina

Název v původním jazyce

FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer

Popis výsledku v původním jazyce

Concurrent chemoradiotherapy represents one of the most used strategies in the curative treatment of patients with head and neck (HNC) cancer. Locoregional failure is the predominant recurrence pattern. Tumor hypoxia belongs to the main cause of treatment failure. Positron emission tomography (PET) using hypoxia radiotracers has been studied extensively and has proven its feasibility and reproducibility to detect tumor hypoxia. A number of studies confirmed that the uptake of FMISO in the recurrent region is significantly higher than that in the non-recurrent region. The escalation of dose to hypoxic tumors may improve outcomes. The technical feasibility of optimizing radiotherapeutic plans has been well documented. To define the hypoxic tumour volume, there are two main approaches: dose painting by contour (DPBC) or by number (DPBN) based on PET images. Despite amazing technological advances, precision in target coverage, and surrounding tissue sparring, radiation oncology is still not considered a targeted treatment if the ""one dose fits all"" approach is used. Using FMISO and other hypoxia tracers may be an important step for individualizing radiation treatment and together with future radiomic principles and a possible genome-based adjusting dose, will move radiation oncology into the precise and personalized era.

Název v anglickém jazyce

FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer

Popis výsledku anglicky

Concurrent chemoradiotherapy represents one of the most used strategies in the curative treatment of patients with head and neck (HNC) cancer. Locoregional failure is the predominant recurrence pattern. Tumor hypoxia belongs to the main cause of treatment failure. Positron emission tomography (PET) using hypoxia radiotracers has been studied extensively and has proven its feasibility and reproducibility to detect tumor hypoxia. A number of studies confirmed that the uptake of FMISO in the recurrent region is significantly higher than that in the non-recurrent region. The escalation of dose to hypoxic tumors may improve outcomes. The technical feasibility of optimizing radiotherapeutic plans has been well documented. To define the hypoxic tumour volume, there are two main approaches: dose painting by contour (DPBC) or by number (DPBN) based on PET images. Despite amazing technological advances, precision in target coverage, and surrounding tissue sparring, radiation oncology is still not considered a targeted treatment if the ""one dose fits all"" approach is used. Using FMISO and other hypoxia tracers may be an important step for individualizing radiation treatment and together with future radiomic principles and a possible genome-based adjusting dose, will move radiation oncology into the precise and personalized era.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30218 - General and internal medicine

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Personalized Medicine

ISSN

2075-4426

e-ISSN

—

Svazek periodika

—

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

000845752300001

EID výsledku v databázi Scopus

2-s2.0-85137386277